Hoever, P. ; Dorffner, G. ; Beneš, H. ; Penzel, T. 
; Danker-Hopfe, H. ; Barbanoj, M. J. ; Pillar, G. ; Saletu, B. ; Polo, O. ; Kunz, D. ; Zeitlhofer, J. ; Berg, S. ; Partinen, M. ; Bassetti, C. L. ; Högl, B. ; Ebrahim, I. O. ; Holsboer-Trachsler, E. ; Bengtsson, H. ; Peker, Y. ; Hemmeter, U.-M. ; Chiossi, E. ; Hajak, Göran ; Dingemanse, J.
; Danker-Hopfe, H. ; Barbanoj, M. J. ; Pillar, G. ; Saletu, B. ; Polo, O. ; Kunz, D. ; Zeitlhofer, J. ; Berg, S. ; Partinen, M. ; Bassetti, C. L. ; Högl, B. ; Ebrahim, I. O. ; Holsboer-Trachsler, E. ; Bengtsson, H. ; Peker, Y. ; Hemmeter, U.-M. ; Chiossi, E. ; Hajak, Göran ; Dingemanse, J. 
Abstract
The orexin system is a key regulator of sleep and wakefulness. In a multicenter, double-blind, randomized, placebo-controlled, two-way crossover study, 161 primary insomnia patients received either the dual orexin receptor antagonist almorexant, at 400, 200, 100, or 50 mg in consecutive stages, or placebo on treatment nights at 1-week intervals. The primary end point was sleep efficiency (SE) ...
Owner only: item control page
Altmetric